Yale University Jul 17 2025 A specially engineered antibody capable of delivering RNA therapies to hard-to-reach, treatment-resistant tumors significantly shrank tumor size and improved survival in animal models, according to a study published July 16 in Science Translational Medicine.   The study provides evidence that, once injected into the bloodstream, the antibody TMAB3, combined with a type of RNA that stimulates an innate immune reaction, can localize to tumors and penetrate and destroy